Core Viewpoint - Crystal Tech Holdings (02228) has successfully delivered an automated workstation for formula stability testing to BASF, enhancing BASF's automation system across various high-value fields such as new drug development and chemical synthesis [1] Group 1: Company Developments - Crystal Tech Holdings' stock rose over 4%, reaching 11.8 HKD with a trading volume of 296 million HKD [1] - The automated workstation delivered to BASF supports a comprehensive automation system for sample management, testing analysis, and data management [1] Group 2: Strategic Partnerships - On February 5, Crystal Tech Holdings announced a project agreement and long-term strategic cooperation with Weisheng Pharmaceutical (02561) [1] - The collaboration aims to integrate Crystal Tech's AI and robotics drug development platform with Weisheng's expertise in the endocrine field, focusing on high clinical value indications and innovative targets [1] - This partnership seeks to advance the early discovery and clinical translation of innovative therapies in the endocrine treatment sector, targeting a market potential worth hundreds of billions [1]